Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427856 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)
A Phase 2 study, sponsored by Gemin X.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00427856 is a Phase 2 study that has completed, run by Gemin X. The registered enrollment target is 7 participants.
The verdict
NCT00427856, a Phase 2 study, has completed, sponsored by Gemin X.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.
Interventions
- DRUG Rituximab
- DRUG Obatoclax mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00427856
The ClinicalTrials.gov registry entry for NCT00427856 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gemin X, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00427856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00427856 about?
NCT00427856 is a clinical study titled "Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)". Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often...
What is the current status of trial NCT00427856?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2007-03. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00427856?
The interventions under investigation include: Rituximab (DRUG), Obatoclax mesylate (DRUG).
Who is sponsoring clinical trial NCT00427856?
This trial is sponsored by Gemin X, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.